Non‐small cell lung cancer in China

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699

Cancer statistics, 2022

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064

Tumor angiogenesis: therapeutic implications

Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593

The 2015 World Health Organization Classification of Lung Tumors

Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190

Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

Cao, W., Chen, H.-D., Yu, Y.-W., Li, N., & Chen, W.-Q. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001474 · Cited by 2,865

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798

Global patterns of cancer incidence and mortality rates and trends

Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557

Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer

(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317

Radiomics: the process and the challenges

Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., Forster, K., Aerts, H. J. W. L., Dekker, A., Fenstermacher, D., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.010 · Cited by 2,258 · cited 1×

Liquid Biopsies: Genotyping Circulating Tumor DNA

Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer

Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916623 · Cited by 1,712

Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater

Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664

Smoking prevalence and cigarette consumption in 187 countries, 1980-2012

Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Shi, Y., Au, J. S.-K., Thongprasert, S., Srinivasan, S., Tsai, C.-M., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G., & Yang, P.-C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,551

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270

A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer

Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig, J., Olazabal, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401203300301 · Cited by 1,261

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

Curran, W. J., Paulus, R., Langer, C. J., Komaki, R., Lee, J. S., Hauser, S., Movsas, B., Wasserman, T., Rosenthal, S. A., Gore, E., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr325 · Cited by 1,233

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151

New driver mutations in non-small-cell lung cancer

Pao, W., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,128

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123

A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer

Roth, J. A., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.9.673 · Cited by 1,111

First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099

Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021

Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,000

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4855 · Cited by 974

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946

Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 939

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors

Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

(2014) · The Lancet · doi:10.1016/s0140-6736(13)62159-5 · Cited by 884

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 870

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862

Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations

Turner, M. C., Andersen, Z. J., Baccarelli, A., Diver, W. R., Gapstur, S. M., Pope, C. A., Prada, D., Samet, J., Thurston, G., & Cohen, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21632 · Cited by 844

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30453-8 · Cited by 841

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005653 · Cited by 828

Disruption of cancer cell replication by alternating electric fields

Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., & Palti, Y. (2004) · Cancer research · doi:10.1158/0008-5472.can-04-0083 · Cited by 827

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

Tsao, M. S., Kerr, K. M., Kockx, M., Beasley, M.-B., Borczuk, A. C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.-Y., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 794

Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database

Paul, S., Altorki, N. K., Sheng, S., Lee, P. C., Harpole, D. H., Onaitis, M. W., Stiles, B. M., Port, J. L., & D'Amico, T. A. (2010) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2009.08.026 · Cited by 789

Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer

Patz, E. F., Pinsky, P., Gatsonis, C., Sicks, J. D., Kramer, B. S., Tammemägi, M. C., Chiles, C., Black, W. C., & Aberle, D. R. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12738 · Cited by 776

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756

Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys

Giovino, G. A., Mirza, S. A., Samet, J. M., Gupta, P. C., Jarvis, M. J., Bhala, N., Peto, R., Zatonski, W., Hsia, J., Morton, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61085-x · Cited by 740

Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

SpiroMeta Consortium, McKay, J. D., Hung, R. J., Han, Y., Zong, X., Carreras-Torres, R., Christiani, D. C., Caporaso, N. E., Johansson, M., Xiao, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3892 · Cited by 720

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 695

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.017 · Cited by 683

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Shaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S., Gainor, J. F., Johnson, M., Dietrich, J., James, L. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30680-0 · Cited by 659

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Ohe, Y., Ohashi, Y., Kubota, K., Tamura, T., Nakagawa, K., Negoro, S., Nishiwaki, Y., Saijo, N., Ariyoshi, Y., & Fukuoka, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl377 · Cited by 633

The effect of air pollution on deaths, disease burden, and life expectancy across China and its provinces, 1990–2017: an analysis for the Global Burden of Disease Study 2017

Yin, P., Brauer, M., Cohen, A. J., Wang, H., Li, J., Burnett, R. T., Stanaway, J. D., Causey, K., Larson, S., Godwin, W., et al. (2020) · The Lancet Planetary Health · doi:10.1016/s2542-5196(20)30161-3 · Cited by 624

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial

Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Zhao, Y., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3039 · Cited by 614

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database

Singal, G., Miller, P. G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., Gossai, A., Frampton, G. M., Torres, A. Z., Lehnert, E. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.3241 · Cited by 549

Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015

Jemal, A., & Fedewa, S. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6416 · Cited by 530

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Socinski, M. A., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.009 · Cited by 529

Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study

The Telomeres Mendelian Randomization Collaboration, Haycock, P. C., Burgess, S., Nounu, A., Zheng, J., Okoli, G. N., Bowden, J., Wade, K. H., Timpson, N. J., Evans, D. M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5945 · Cited by 513

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Camidge, D. R., Dziadziuszko, R., Peters, S., Mok, T., Noe, J., Nowicka, M., Gadgeel, S. M., Cheema, P., Pavlakis, N., de Marinis, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.007 · Cited by 490

New and emerging targeted treatments in advanced non-small-cell lung cancer

Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 487

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30365-9 · Cited by 483

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Hosomi, Y., Morita, S., Sugawara, S., Kato, T., Fukuhara, T., Gemma, A., Takahashi, K., Fujita, Y., Harada, T., Minato, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01488 · Cited by 481

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468

Induction Chemoradiation and Surgical Resection for Superior Sulcus Non–Small-Cell Lung Carcinomas: Long-Term Results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)

Rusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Winton, T., Johnson, D. H., Shulman, L., Shepherd, F., Deschamps, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2826 · Cited by 457

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Senan, S., Brade, A., Wang, L.-H., Vansteenkiste, J., Dakhil, S., Biesma, B., Martinez Aguillo, M., Aerts, J., Govindan, R., Rubio-Viqueira, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8824 · Cited by 433

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

Felip, E., Rosell, R., Maestre, J. A., Rodríguez-Paniagua, J. M., Morán, T., Astudillo, J., Alonso, G., Borro, J. M., González-Larriba, J. L., Torres, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6204 · Cited by 430

Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10

Butts, C. A., Ding, K., Seymour, L., Twumasi-Ankrah, P., Graham, B., Gandara, D., Johnson, D. H., Kesler, K. A., Green, M., Vincent, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0333 · Cited by 425

Using Deep Learning for Classification of Lung Nodules on Computed Tomography Images

Song, Q., Zhao, L., Luo, X., & Dou, X. (2017) · Journal of Healthcare Engineering · doi:10.1155/2017/8314740 · Cited by 422

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer

Noronha, V., Patil, V. M., Joshi, A., Menon, N., Chougule, A., Mahajan, A., Janu, A., Purandare, N., Kumar, R., More, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01154 · Cited by 418

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.017 · Cited by 401

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Wang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0366 · Cited by 396

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 395

Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

Arriagada, R., Dunant, A., Pignon, J.-P., Bergman, B., Chabowski, M., Grunenwald, D., Kozlowski, M., Le Péchoux, C., Pirker, R., Pinel, M.-I. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2272 · Cited by 394

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.014 · Cited by 390

Cancer incidence and mortality in China, 2015

Zhang, S., Sun, K., Zheng, R., Zeng, H., Wang, S., Chen, R., Wei, W., & He, J. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2020.12.001 · Cited by 389

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Zhou, C., Wu, Y.-L., Chen, G., Liu, X., Zhu, Y., Lu, S., Feng, J., He, J., Han, B., Wang, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4424 · Cited by 372

A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese

Hu, Z., Wu, C., Shi, Y., Guo, H., Zhao, X., Yin, Z., Yang, L., Dai, J., Hu, L., Tan, W., et al. (2011) · Nature Genetics · doi:10.1038/ng.875 · Cited by 367

Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

Smit, E. F., van Meerbeeck, J. P. A. M., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 351

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., Lee, K. H., Delmonte, A., García Campelo, M. R., Kim, D.-W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00505 · Cited by 351

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Novello, S., Mazières, J., Oh, I.-J., de Castro, J., Migliorino, M. R., Helland, Å., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeaiter, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy121 · Cited by 335

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

Takahashi, T., Sonobe, M., Kobayashi, M., Yoshizawa, A., Menju, T., Nakayama, E., Mino, N., Iwakiri, S., Sato, K., Miyahara, R., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0808-7 · Cited by 326

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

Wu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.011 · Cited by 322

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)

Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02752 · Cited by 322

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Gadgeel, S., Peters, S., Mok, T., Shaw, A. T., Kim, D. W., Ou, S. I., Pérol, M., Wrona, A., Novello, S., Rosell, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy405 · Cited by 318

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.018 · Cited by 315

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Nogami, N., Barlesi, F., Socinski, M. A., Reck, M., Thomas, C. A., Cappuzzo, F., Mok, T. S. K., Finley, G., Aerts, J. G., Orlandi, F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.014 · Cited by 302

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement

Lim, S. M., Kim, H. R., Lee, J.-S., Lee, K. H., Lee, Y.-G., Min, Y. J., Cho, E. K., Lee, S. S., Kim, B.-S., Choi, M. Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3701 · Cited by 301

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

Zhou, C., Ramalingam, S. S., Kim, T. M., Kim, S.-W., Yang, J. C.-H., Riely, G. J., Mekhail, T., Nguyen, D., Garcia Campelo, M. R., Felip, E., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4761 · Cited by 291

Particulate matter air pollution components and risk for lung cancer

Raaschou-Nielsen, O., Beelen, R., Wang, M., Hoek, G., Andersen, Z. J., Hoffmann, B., Stafoggia, M., Samoli, E., Weinmayr, G., Dimakopoulou, K., et al. (2016) · Environment International · doi:10.1016/j.envint.2015.11.007 · Cited by 288

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Yue, D., Xu, S., Wang, Q., Li, X., Shen, Y., Zhao, H., Chen, C., Mao, W., Liu, W., Liu, J., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30277-7 · Cited by 288

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.005 · Cited by 284

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Zhou, C., Kim, S.-W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J.-J., Cheng, Y., Lee, S.-H., Bu, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30053-0 · Cited by 273

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Wei, Y.-C., Liu, Y.-Y., Chen, C., Cheng, Y., Yin, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01820 · Cited by 273

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial

Jabbour, S. K., Lee, K. H., Frost, N., Breder, V., Kowalski, D. M., Pollock, T., Levchenko, E., Reguart, N., Martinez-Marti, A., Houghton, B., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2301 · Cited by 270

Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations

Dai, J., Lv, J., Zhu, M., Wang, Y., Qin, N., Ma, H., He, Y.-Q., Zhang, R., Tan, W., Fan, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30144-4 · Cited by 265

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Scheffler, M., Ihle, M. A., Hein, R., Merkelbach-Bruse, S., Scheel, A. H., Siemanowski, J., Brägelmann, J., Kron, A., Abedpour, N., Ueckeroth, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.013 · Cited by 264

Fruits, vegetables and lung cancer risk: a systematic review and meta-analysis

Vieira, A. R., Abar, L., Vingeliene, S., Chan, D. S. M., Aune, D., Navarro-Rosenblatt, D., Stevens, C., Greenwood, D., & Norat, T. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv381 · Cited by 264

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Kohno, T., Nakaoku, T., Tsuta, K., Tsuchihara, K., Matsumoto, S., Yoh, K., & Goto, K. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2014.11.11 · Cited by 263

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04

Ahn, J. S., Ahn, Y. C., Kim, J.-H., Lee, C. G., Cho, E. K., Lee, K. C., Chen, M., Kim, D.-W., Kim, H.-K., Min, Y. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0130 · Cited by 261

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial

Horn, L., Wang, Z., Wu, G., Poddubskaya, E., Mok, T., Reck, M., Wakelee, H., Chiappori, A. A., Lee, D. H., Breder, V., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3523 · Cited by 252

Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial

Pisters, K. M. W., Vallières, E., Crowley, J. J., Franklin, W. A., Bunn, P. A., Ginsberg, R. J., Putnam, J. B., Chansky, K., & Gandara, D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1685 · Cited by 247

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

Zhou, Q., Chen, M., Jiang, O., Pan, Y., Hu, D., Lin, Q., Wu, G., Cui, J., Chang, J., Cheng, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00630-6 · Cited by 244

Lung Cancer in People’s Republic of China

Gao, S., Li, N., Wang, S., Zhang, F., Wei, W., Li, N., Bi, N., Wang, Z., & He, J. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.028 · Cited by 237

A Decade of GWAS Results in Lung Cancer

Bossé, Y., & Amos, C. I. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0794 · Cited by 235

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

El Osta, B., Behera, M., Kim, S., Berry, L. D., Sica, G., Pillai, R. N., Owonikoko, T. K., Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.020 · Cited by 232

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Zhou, C., Wang, Z., Sun, Y., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Chang, J., Chen, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00650-1 · Cited by 230

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., Chang, Q., Zhang, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.026 · Cited by 227

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Jänne, P. A., Govindan, R., Evans, T. L., Costa, D. B., Wakelee, H. A., Heist, R. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00131 · Cited by 210

Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80.

Harris, J. E. (1983) · PubMed · Cited by 209

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Lu, S., Fang, J., Li, X., Cao, L., Zhou, J., Guo, Q., Liang, Z., Cheng, Y., Jiang, L., Yang, N., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00084-9 · Cited by 207

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Zhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00297 · Cited by 205

Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial

Liang, J., Bi, N., Wu, S., Chen, M., Lv, C., Zhao, L., Shi, A., Jiang, W., Xu, Y., Zhou, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx009 · Cited by 196

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

He, J., Su, C., Liang, W., Xu, S., Wu, L., Fu, X., Zhang, X., Ge, D., Chen, Q., Mao, W., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00134-x · Cited by 185

Cancer Risks After Radiation Exposure in Middle Age

Shuryak, I., Sachs, R. K., & Brenner, D. J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq346 · Cited by 182

The short-term association between asthma hospitalisations, ambient temperature, other meteorological factors and air pollutants in Hong Kong: a time-series study

Lam, H. C.-Y., Li, A. M., Chan, E. Y.-Y., & Goggins, W. B. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-208054 · Cited by 182

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Cheng, Y., Murakami, H., Yang, P.-C., He, J., Nakagawa, K., Kang, J. H., Kim, J.-H., Wang, X., Enatsu, S., Puri, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9218 · Cited by 182

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Wu, Y.-L., Lu, S., Lu, Y., Zhou, J., Shi, Y.-K., Sriuranpong, V., Ho, J. C. M., Ong, C. K., Tsai, C.-M., Chung, C.-H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.012 · Cited by 179

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

West, H., McCleland, M. L., Cappuzzo, F., Reck, M., Mok, T. S. K., Jotte, R. M., Nishio, M., Kim, E., Morris, S., Zou, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003027 · Cited by 176

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Cheng, Y., He, Y., Li, W., Zhang, H.-L., Zhou, Q., Wang, B., Liu, C., Walding, A., Saggese, M., Huang, X., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00794-6 · Cited by 170

Lifestyle and Cancer Risk

Katzke, V. A., Kaaks, R., & Kühn, T. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000101 · Cited by 168

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

Yang, J. C.-H., Camidge, D. R., Yang, C.-T., Zhou, J., Guo, R., Chiu, C.-H., Chang, G.-C., Shiah, H.-S., Chen, Y., Wang, C.-C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.001 · Cited by 165

Radiomics analysis of pulmonary nodules in low‐dose CT for early detection of lung cancer

Choi, W., Oh, J. H., Riyahi, S., Liu, C., Jiang, F., Chen, W., WHITE, C. S., Rimner, A., Mechalakos, J., Deasy, J. O., et al. (2018) · Medical Physics · doi:10.1002/mp.12820 · Cited by 163

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Wu, Y.-L. L. C., John, T., Grohé, C., Majem, M., Goldman, J. W., Kim, S., Kato, T., Лактионов, К. К., Vũ, H. V., Wang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.014 · Cited by 162

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Kang, J., Zhang, C., & Zhong, W. (2021) · Cancer Communications · doi:10.1002/cac2.12153 · Cited by 160

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study

Han, B., Tjulandin, S., Hagiwara, K., Normanno, N., Wulandari, L., Лактионов, К. К., Hudoyo, A., He, Y., Zhang, Y., Wang, M.-Z., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.021 · Cited by 159

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

Dietel, M., Savelov, N., Salanova, R., Micke, P., Bigras, G., Hida, T., Antunez, J., Guldhammer Skov, B., Hutarew, G., Sua, L. F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.012 · Cited by 158

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

Gazdar, A. F., Robinson, L. D., Oliver, D., Xing, C., Travis, W. D., Soh, J., Toyooka, S., Watumull, L. M., Xie, Y., Kernstine, K. H., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000130 · Cited by 156

Effect of the Interaction Between Outdoor Air Pollution and Extreme Temperature on Daily Mortality in Shanghai, China

Cheng, Y., & Kan, H. (2011) · Journal of Epidemiology · doi:10.2188/jea.je20110049 · Cited by 155

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Lü, S., Wang, Q., Zhang, G., Dong, X., Yang, C., Song, Y., Chang, G., Lü, Y., Pan, H., Chiu, C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.024 · Cited by 154

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Yang, Y., Zhou, J., Zhou, J., Feng, J., Zhuang, W., Chen, J., Zhao, J., Zhong, W., Zhao, Y., Zhang, Y., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30252-8 · Cited by 149

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8503 · Cited by 146

Screening for Lung Cancer

Bach, P. B., Silvestri, G. A., Hanger, M., & Jett, J. R. (2007) · CHEST Journal · doi:10.1378/chest.07-1349 · Cited by 144

Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population

Dong, J., Hu, Z., Wu, C. H., Guo, H., Zhou, B., Lv, J., Lu, D., Chen, K., Shi, Y., Chu, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2351 · Cited by 143

Brigatinib: First Global Approval

Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0776-3 · Cited by 143

Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

Han, B., Jin, B., Chu, T., Niu, Y., Dong, Y., Xu, J., Gu, A., Zhong, H., Wang, H., Zhang, X., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30806 · Cited by 141

Short-term association between ambient air pollution and lung cancer mortality

Wang, N., Mengersen, K. L., Tong, S., Kimlin, M. G., Zhou, M., Wang, L., Yin, P., Xu, Z., Cheng, J., Zhang, Y., et al. (2019) · Environmental Research · doi:10.1016/j.envres.2019.108748 · Cited by 140

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Spicer, J., Wang, C., Tanaka, F., Saylors, G. B., Chen, K.-N., Liberman, M., Vokes, E. E., Girard, N., Lu, S., Provencio, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.8503 · Cited by 139

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations

Tissot, C., Couraud, S., Tanguy, R., Bringuier, P., Girard, N., & Souquet, P.-J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.006 · Cited by 138

Liquid biopsy for lung cancer early detection

Santarpía, M., Liguori, A., D’Aveni, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., Lazzari, C., Altavilla, G., & Rosell, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.81 · Cited by 138

Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening

Yang, W., Qian, F., Teng, J., Wang, H., Manegold, C., Pilz, L. R., Voigt, W., Zhang, Y., Ye, J., Chen, Q., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.003 · Cited by 135

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Paz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., Kazarnowicz, A., Losonczy, G., de Castro, G., Szczesna, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70046-x · Cited by 133

Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin

Pujol, J.-L., Breton, J.-L., Gervais, R., Rebattu, P., Depierre, A., Morère, J., Milleron, B. J., Debieuvre, D., Castera, D., Souquet, P. J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi126 · Cited by 129

Epidemiology: The dominant malignancy

Bender, E. (2014) · Nature · doi:10.1038/513s2a · Cited by 127

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Shi, Y., Hu, X., Zhang, S., Lv, D., Wu, L., Yu, Q., Zhang, Y., Liu, L., Wang, X., Cheng, Y., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30455-0 · Cited by 125

Depression and the development of cancer: a meta-analysis.

McGee, R., Williams, S., & Elwood, M. (1994) · Social Science & Medicine (1967) · doi:10.1016/0277-9536(94)90314-x · Cited by 123

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer

Chen, X., Zhou, F., Li, X., Yang, G., Zhang, L., Ren, S., Zhao, C., Deng, Q., Li, W., Gao, G., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000606 · Cited by 117

Projected Outcomes Using Different Nodule Sizes to Define a Positive CT Lung Cancer Screening Examination

Gierada, D. S., Pinsky, P. F., Nath, H. P., Chiles, C., Duan, F., & Aberle, D. R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju284 · Cited by 111

Targeting EGFR in Lung Cancer: Current Standards and Developments

Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108

A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer

Pless, M., Droege, C., von Moos, R., Salzberg, M. O., & Betticher, D. C. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.06.025 · Cited by 106

Folate Receptor-Positive Circulating Tumor Cells as a Novel Diagnostic Biomarker in Non-Small Cell Lung Cancer

Yu, Y., Chen, Z., Dong, J., Wei, P., Hu, R., Zhou, C., Sun, N., Luo, M., Yang, W., Yao, R., et al. (2013) · Translational Oncology · doi:10.1593/tlo.13535 · Cited by 104

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer

Liang, W., Cai, K., Chen, C., Chen, H., Chen, Q., Fu, J., Hu, J., Jiang, T., Jiao, W., Li, S., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-2020-63 · Cited by 104

Plasma DNA Quantification in Lung Cancer Computed Tomography Screening

Sozzi, G., Roz, L., Conte, D., Mariani, L., Andriani, F., Vullo, S. L., Verri, C., & Pastorino, U. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200807-1068oc · Cited by 103

Lung Cancer in Republic of China

Luo, Y., Chiu, C., Kuo, C.-H. S., Chou, T., Yeh, Y., Hsu, H., Yen, S.-H., Wu, Y., Yang, J. C., Liao, B.-C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.155 · Cited by 102

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer

Desai, A. P., Abdayem, P., Adjei, A. A., & Planchard, D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.002 · Cited by 94

Estimation of heritability for nine common cancers using data from genome‐wide association studies in Chinese population

Dai, J., Shen, W., Wen, W., Chang, J., Wang, T., Chen, H., Jin, G., Ma, H., Wu, C. H., Li, L., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30447 · Cited by 92

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF

Zhuang, X., Zhao, C., Li, J., Su, C., Chen, X., Ren, S., Li, X., & Zhou, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2183 · Cited by 92

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study

Kreuter, M., Vansteenkiste, J., Fischer, J. R., Eberhardt, W., Zabeck, H., Kollmeier, J., Serke, M. H., Frickhofen, N., Reck, M., Engel-Riedel, W., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds578 · Cited by 89

[China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2018 version)].

Zhou, Q., Fan, Y., Wang, Y., Qiao, Y., Wang, G., Huang, Y., Wang, X., Wu, N., Zhang, G., Zheng, X., et al. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.02.01 · Cited by 86

Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses

Khankari, N. K., Shu, X., Wen, W., Kraft, P. L., Lindström, S., Peters, U., Schildkraut, J., Schumacher, F. R., Paolo, B., Risch, A., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002118 · Cited by 83

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Wang, R., Zhang, Y., Pan, Y., Li, Y., Hu, H., Cai, D., Li, H., Ye, T., Luo, X., Zhang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5549 · Cited by 82

Estimation of Overdiagnosis of Lung Cancer in Low-Dose Computed Tomography Screening

Heleno, B., Siersma, V., & Brodersen, J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.3056 · Cited by 82

Is high vitamin B12 status a cause of lung cancer?

Fanidi, A., Carreras‐Torres, R., Larose, T. L., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32033 · Cited by 79

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Shi, M., Gu, A., Tu, H., Huang, C., Wang, H., Yu, Z., Wang, X., Cao, L., Shu, Y., Wang, H., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.479 · Cited by 79

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Liu, S. M., Sun, H., Zhou, J., Jie, G., Xie, Z., Shao, Y. W., Zhang, X., Ye, J., Chen, C., Zhang, X., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-00199-z · Cited by 76

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

Lee, J., Chaft, J. E., Nicholas, A., Patterson, A., Waqar, S. N., Toloza, E. M., Haura, E. B., Raz, D. J., Reckamp, K. L., Merritt, R. E., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.320 · Cited by 76

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients

Sutiman, N., Tan, S. W., Tan, E. H., Lim, W. T., Kanesvaran, R., Ng, Q. S., Jain, A., Ang, M., Tan, W. L., Toh, C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2225 · Cited by 75

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Wang, Y., Zhang, S., Wu, F., Zhao, J., Li, X., Zhao, C., Ren, S., & Zhou, C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4277-x · Cited by 74

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).

Gainor, J. F., Curigliano, G., Kim, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9515 · Cited by 74

Quantification of Rare Circulating Tumor Cells in Non-Small Cell Lung Cancer by Ligand-Targeted PCR

Lou, J., Ben, S., Yang, G., Liang, X., Wang, X., Ni, S., & Han, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080458 · Cited by 71

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

Zhang, J., Pan, Y., Shi, Q., Zhang, G., Jiang, L., Dong, X., Gu, K., Wang, H., Zhang, X., Yang, N., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12225 · Cited by 69

Emerging role of exosomes in cancer therapy: progress and challenges

Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297

Hypoxia-induced circ_0017521 enhances glycolysis and promotes NSCLC progression via upregulating the PFKFB3/PI3K-AKT pathway

Zhu, J., Yan, J., Zhang, Y., Zhu, X., & Chen, G. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10202-x · Cited by 3